COPD — Stable Management and Acute Exacerbation

Chronic obstructive pulmonary disease (COPD) is a progressive, preventable, and treatable disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities, usually caused by significant exposure to noxious particles or gases.

[KEY_CONCEPT] COPD encompasses two main phenotypes: emphysema (destruction of alveolar walls leading to enlarged air spaces) and chronic bronchitis (chronic productive cough for ≥3 months in each of 2 consecutive years).

Epidemiology

• Fourth leading cause of death worldwide
• Affects ~16 million Americans, with millions more undiagnosed
• Primary risk factor: Cigarette smoking (85-90% of cases)
• Other risk factors: α1-antitrypsin deficiency, occupational exposures, air pollution, biomass fuel exposure

Pathophysiology

Airway obstruction results from:

1. Mucus hypersecretion and ciliary dysfunction
2. Airway inflammation and fibrosis
3. Loss of elastic recoil due to alveolar destruction
4. Air trapping and hyperinflation

[HIGH_YIELD] The hallmark spirometric finding is post-bronchodilator FEV₁/FVC ratio <0.70, indicating irreversible airflow limitation.

GOLD Classification by Airflow Limitation:

[CLINICAL_PEARL] COPD severity assessment now incorporates both spirometry and clinical symptoms (CAT score or mMRC dyspnea scale) rather than FEV₁ alone.

Stable COPD Presentation

Classic triad: Chronic cough, sputum production, and progressive dyspnea

Respiratory Symptoms

• Chronic productive cough (often first symptom)
• Progressive dyspnea on exertion → at rest
• Wheezing and chest tightness
• Frequent respiratory infections

[HIGH_YIELD] Pink puffer (emphysema predominant) vs Blue bloater (chronic bronchitis predominant) are classic phenotypes:

Physical Examination Findings

• Inspection: Barrel chest, use of accessory muscles, pursed-lip breathing
• Percussion: Hyperresonance, decreased diaphragmatic excursion
• Auscultation: Diminished breath sounds, prolonged expiratory phase, wheeze
• Advanced disease: Cyanosis, clubbing, signs of right heart failure

COPD Exacerbation Presentation

[KEY_CONCEPT] COPD exacerbation is defined as acute worsening of respiratory symptoms beyond normal day-to-day variations requiring additional therapy.

Anthonisen Criteria for Exacerbation Severity:

1. Type I (severe): All 3 present
   • Increased dyspnea
   • Increased sputum volume
   • Increased sputum purulence
2. Type II (moderate): 2 of 3 present
3. Type III (mild): 1 of 3 present plus URI, fever, wheeze, or increased cough

[CLINICAL_PEARL] Look for precipitating factors: respiratory infections (bacterial/viral), air pollution, medication noncompliance, pneumothorax, or pulmonary embolism.

Diagnostic Workup

Spirometry (Gold Standard)

[HIGH_YIELD] Post-bronchodilator FEV₁/FVC <0.70 confirms airflow limitation

• Perform 15-20 minutes after bronchodilator administration
• Irreversible obstruction (minimal response to bronchodilators) distinguishes COPD from asthma

Laboratory Studies

• CBC: Evaluate for polycythemia (chronic hypoxemia) or anemia
• α1-antitrypsin level: If early-onset COPD or minimal smoking history
• ABG: In severe disease or suspected hypercapnia

Imaging

• Chest X-ray: Hyperinflation, flattened diaphragms, increased AP diameter
• CT chest: Gold standard for emphysema detection, rule out complications

COPD Assessment Test (CAT) Score

Symptom assessment tool (0-40 points):

• 0-10: Low impact
• 11-20: Medium impact
• 21-30: High impact
• 31-40: Very high impact

Differential Diagnosis

COPD vs Asthma Differentiation:

┌─ Age of onset ─┐ │ COPD: >40 years │ │ Asthma: Any age │ └─────────────────┘ │ ┌─ Smoking history ─┐ │ COPD: Usually >20 │ │ pack-years │ │ Asthma: Variable │ └────────────────────┘ │ ┌─ Reversibility ─┐ │ COPD: <12% or │ │ <200mL FEV₁ │ │ improvement │ │ Asthma: >12% and │ │ >200mL │ └──────────────────┘

Assessment of Exacerbations

COPD Exacerbation Diagnostic Criteria:

• ✓ Acute worsening of baseline dyspnea, cough, or sputum production
• ✓ Beyond normal day-to-day variation
• ✓ Requires change in medication

Severity Assessment:

• Mild: Treat at home with bronchodilators ± antibiotics
• Moderate: May require ED visit or hospitalization
• Severe: Requires hospitalization, may need ICU care

[CLINICAL_PEARL] Red flags requiring immediate hospitalization: severe dyspnea, altered mental status, hemodynamic instability, or failure of outpatient treatment.

Pharmacological Management

GOLD 2023 Treatment Algorithm

Stable COPD Treatment Approach:

Group A (Low symptoms, Low risk) ├─ Bronchodilator (SABA or LABA or LAMA)

Group B (High symptoms, Low risk)
├─ LABA or LAMA ├─ If persistent symptoms → LABA + LAMA

Group E (High symptoms, High risk) ├─ LABA + LAMA ├─ If eosinophils ≥300 → Consider ICS + LABA + LAMA ├─ If frequent exacerbations → Triple therapy

Bronchodilator Therapy

[HIGH_YIELD] LAMA (long-acting anticholinergics) are preferred initial therapy for most patients due to superior efficacy in reducing exacerbations compared to LABA.

Inhaled Corticosteroids (ICS)

Indications for ICS:

• Blood eosinophils ≥300 cells/μL
• Frequent exacerbations (≥2 moderate or ≥1 requiring hospitalization)
• History of asthma-COPD overlap

[CLINICAL_PEARL] Triple therapy (ICS + LABA + LAMA) is reserved for patients with frequent exacerbations despite dual bronchodilator therapy.

Non-Pharmacological Management

Pulmonary Rehabilitation

• Gold standard non-pharmacological intervention
• Improves exercise capacity, quality of life, and reduces hospitalizations
• Includes exercise training, education, and behavioral modification

Oxygen Therapy

Long-term oxygen therapy (LTOT) indications:

• PaO₂ ≤55 mmHg or SpO₂ ≤88%
• PaO₂ 56-59 mmHg with evidence of cor pulmonale or polycythemia
• Goal: ≥15 hours/day, target SpO₂ 88-92%

Vaccinations

• Annual influenza vaccine
• Pneumococcal vaccines: PCV20 or PCV15 + PPSV23
• COVID-19 vaccination

[KEY_CONCEPT] Smoking cessation is the most important intervention to slow disease progression. Consider pharmacotherapy (varenicline, bupropion, or nicotine replacement) combined with counseling.

Emergency Department/Hospital Management

Initial Assessment and Stabilization

COPD Exacerbation Management Algorithm:

┌─ ABC Assessment ─┐ │ • Airway patent │ │ • Breathing │ │ • Circulation │ └──────────────────┘ │ ┌─ Immediate Interventions ─┐ │ • O₂ therapy (target │ │ SpO₂ 88-92%) │ │ • Bronchodilators │ │ • Systemic steroids │ └──────────────────────────┘ │ ┌─ Assess Need for ─┐ │ • Antibiotics │ │ • NIV/Intubation │ │ • ICU admission │ └───────────────────┘

Pharmacological Treatment

1. Bronchodilators (First-line)

• SABA: Albuterol 2.5-5mg nebulized Q20min × 3, then Q2-4h
• SAMA: Ipratropium 0.5mg nebulized Q6h
• [HIGH_YIELD] Combination therapy (albuterol + ipratropium) more effective than either alone

2. Systemic Corticosteroids

• Prednisolone 40mg daily × 5 days (GOLD recommendation)
• Reduces treatment failure, shortens recovery time
• [CLINICAL_PEARL] Shorter courses (5 days) as effective as longer courses with fewer side effects

3. Antibiotics Indications (Anthonisen criteria):

• Type I exacerbations (all 3 symptoms)
• Type II with increased sputum purulence
• Mechanical ventilation required

Antibiotic Choices:

Oxygen Therapy

[KEY_CONCEPT] Controlled oxygen therapy: Target SpO₂ 88-92%

• Avoid excessive oxygen (risk of CO₂ retention)
• Use Venturi masks for precise FiO₂ control
• Monitor ABGs if concerns about hypercapnia

Non-Invasive Ventilation (NIV)

Indications for NIV:

• Persistent hypercapnic respiratory failure (pH <7.35, PCO₂ >45 mmHg)
• Severe dyspnea with accessory muscle use
• Failure to improve with initial medical therapy

NIV Contraindications:

• Hemodynamic instability
• Altered mental status/inability to cooperate
• Copious secretions
• Recent upper airway surgery

Invasive Mechanical Ventilation

Intubation Criteria:

• Failure of NIV or NIV contraindicated
• Severe acidosis (pH <7.25)
• Respiratory arrest or impending arrest
• Hemodynamic instability

[CLINICAL_PEARL] Use lung-protective ventilation strategy: low tidal volumes (6-8 mL/kg IBW), PEEP 5-10 cmH₂O, permissive hypercapnia if pH >7.20.

Acute Complications

Respiratory Failure

Type I (Hypoxemic)

• PaO₂ <60 mmHg with normal or low PCO₂
• Due to V/Q mismatch
• Treatment: Oxygen therapy, bronchodilators

Type II (Hypercapnic)

• PCO₂ >50 mmHg with respiratory acidosis
• Due to ventilation failure
• Treatment: NIV, possible intubation

Pneumothorax

• Spontaneous pneumothorax risk increased in emphysema
• Consider in patients with sudden worsening dyspnea
• CESAR trial showed benefit of video-assisted thoracoscopic surgery for recurrent pneumothorax

Acute Cor Pulmonale

• Right heart strain secondary to pulmonary hypertension
• Signs: JVD, peripheral edema, tricuspid regurgitation murmur
• Treatment: Optimize oxygenation, diuretics for volume overload

Chronic Complications

Chronic Cor Pulmonale

• Develops in advanced COPD (FEV₁ <35%)
• Pulmonary hypertension leads to right heart failure
• Treatment: LTOT, diuretics, pulmonary vasodilators in select cases

Osteoporosis

• 3-fold increased fracture risk
• Risk factors: ICS use, physical inactivity, systemic inflammation
• Prevention: Calcium, vitamin D, bisphosphonates if indicated

Depression and Anxiety

• Present in 40-50% of COPD patients
• Associated with worse outcomes and quality of life
• Screen regularly, treat appropriately

Disease Monitoring

COPD Assessment Parameters:

• Spirometry: Annually or with symptom changes
• Symptom scores: CAT or mMRC at each visit
• Exacerbation history: Frequency and severity
• Exercise tolerance: 6-minute walk test

[HIGH_YIELD] BODE Index predicts mortality:

• BMI
• Obstruction (FEV₁)
• Dyspnea (mMRC scale)
• Exercise capacity (6-minute walk distance)

Prognosis

Factors Affecting Prognosis

Poor prognostic indicators:

• Advanced age
• Severe airflow obstruction (FEV₁ <30%)
• Frequent exacerbations (≥2 per year)
• Comorbidities (cardiovascular disease, lung cancer)
• Continued smoking
• Weight loss/low BMI

Survival Data

• 5-year survival: ~70% overall
• GOLD Stage 4: 5-year survival ~30-50%
• Exacerbation impact: Each hospitalization reduces life expectancy

[CLINICAL_PEARL] Palliative care consultation should be considered for patients with advanced COPD (FEV₁ <30%, oxygen-dependent, frequent hospitalizations) to address symptom management and advance directives.